SEC Form 4 · accession 0002048497-26-000009
Beta Bionics, Inc. · BBNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Hopman
Officer — Chief Commercial Officer
Period of report
Jun 24, 2026
Accepted (ET)
Jun 25, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001674632
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 24, 2026 | S | 1,258 | $15.0083 | D | 129,354 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
- F2The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.